Open AccessWindow-of-Opportunity Study of Valproic Acid in Breast Cancer Testing a Gene Expression Biomarker
Author(s) -
Adam L. Cohen,
Leigh Neumayer,
Ken Boucher,
Rachel E. Factor,
Gajendra Shrestha,
Mark Wade,
John G. Lamb,
Kylee Arbogast,
Stephen Piccolo,
Joanna Riegert,
Matthias C. Schabel,
Andrea Bild,
Theresa L. Werner
Publication year - 2017
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.16.00011
Subject(s) - breast cancer , tolerability , medicine , valproic acid , adverse effect , biomarker , peripheral blood mononuclear cell , cancer , biopsy , oncology , biology , epilepsy , in vitro , biochemistry , psychiatry
The anticancer activity of valproic acid (VPA) is attributed to the inhibition of histone deacetylase. We previously published the genomically derived sensitivity signature for VPA (GDSS-VPA), a gene expression biomarker that predicts breast cancer sensitivity to VPA in vitro and in vivo. We conducted a window-of-opportunity study that examined the tolerability of VPA and the ability of the GDSS-VPA to predict biologic changes in breast tumors after treatment with VPA.